Technical Analysis for MACK - Merrimack Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 7.04 6.34% 0.42
MACK closed up 6.34 percent on Thursday, April 15, 2021, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: May 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical MACK trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Stochastic Reached Overbought Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.34%
Slingshot Bearish Bearish Swing Setup 4.76%
Crossed Above 20 DMA Bullish 4.76%
MACD Bullish Signal Line Cross Bullish 4.76%
Older End-of-Day Signals for MACK ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Upper Bollinger Band Resistance about 15 hours ago
60 Minute Opening Range Breakdown about 16 hours ago
50 DMA Resistance about 16 hours ago
Gap Up Partially Closed about 17 hours ago
60 Minute Opening Range Breakout about 17 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Merrimack Pharmaceuticals, Inc. Description

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer in the United States. The company uses its Network Biology proprietary systems biology-based approach to biomedical research. Its therapeutic oncology candidates in clinical development include MM-398, a stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan, which is in multiple ongoing Phase I, Phase II, Phase III clinical trials for various cancers; MM-121, a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in cancer, which is in multiple ongoing Phase I and Phase II clinical trials; and MM-111, a bispecific antibody designed to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 cell receptor, which is in multiple ongoing Phase I and Phase II clinical trials. The company's product candidates also include MM-302, a nanotherapeutic encapsulation of doxorubicin with attached antibodies that target the ErbB2 (HER2) receptor in Phase 1 clinical trial in patients with advanced ErbB2 positive breast cancer; MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trial; and MM-141, a human tetravalent bispecific antibody designed to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor(IGF-1R) and ErbB3, which is in Phase 1 clinical trial. It has collaboration and license agreements with Sanofi; Dyax Corp.; PharmaEngine, Inc.; Adimab LLC; University of California; U.S. Public Health Service; and Selexis SA. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Biology Clinical Development Treatment Of Cancer Antibodies Cancers Monoclonal Antibody Breast Cancer Treatment Of Breast Cancer Chemotherapy Insulin Cancer Cell Medical Research Public Health Epidermal Growth Factor Receptor Tyrosine Kinase Receptors Her2 Companion Diagnostic Her2/Neu Systems Biology mTOR Doxorubicin Mm 151 Pi3k/Akt/Mtor Pathway

Is MACK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 9.45
52 Week Low 3.0601
Average Volume 89,701
200-Day Moving Average 5.27
50-Day Moving Average 6.92
20-Day Moving Average 6.44
10-Day Moving Average 6.43
Average True Range 0.39
ADX 10.37
+DI 28.27
-DI 17.10
Chandelier Exit (Long, 3 ATRs ) 6.03
Chandelier Exit (Short, 3 ATRs ) 7.09
Upper Bollinger Band 6.92
Lower Bollinger Band 5.97
Percent B (%b) 1.13
BandWidth 14.70
MACD Line -0.06
MACD Signal Line -0.15
MACD Histogram 0.0899
Fundamentals Value
Market Cap 94.2 Million
Num Shares 13.4 Million
EPS 0.10
Price-to-Earnings (P/E) Ratio 70.40
Price-to-Sales 0.00
Price-to-Book 3.06
PEG Ratio 0.07
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.74
Resistance 3 (R3) 7.72 7.45 7.63
Resistance 2 (R2) 7.45 7.27 7.47 7.59
Resistance 1 (R1) 7.25 7.16 7.35 7.27 7.55
Pivot Point 6.98 6.98 7.03 7.00 6.98
Support 1 (S1) 6.78 6.80 6.88 6.81 6.53
Support 2 (S2) 6.51 6.69 6.53 6.49
Support 3 (S3) 6.31 6.51 6.45
Support 4 (S4) 6.34